lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ensysce Biosciences
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
May 9, 2026
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
May 6, 2026
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
May 5, 2026
Ensysce Biosciences Initiates Live “Ask Me Anything” (AMA) Session Highlighting Growth and Future Plans
April 30, 2026
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
April 29, 2026
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
April 28, 2026
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
April 28, 2026
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
March 31, 2026
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 28, 2026
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 21, 2026
1
2
Next Page
→